<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869098</url>
  </required_header>
  <id_info>
    <org_study_id>H-2020-131</org_study_id>
    <nct_id>NCT04869098</nct_id>
  </id_info>
  <brief_title>Effects of an Evening PROtein PrEload on Metabolic Health in Night ShIfT Workers (PROPENSITy)</brief_title>
  <acronym>PROPENSITy</acronym>
  <official_title>Effects of an Evening PROtein PrEload on Blood Glucose, Metabolic Health, and Gut Hormone Release in Night ShIfT Workers (PROPENSITy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Adelaide</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Adelaide</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effects of a whey protein supplement or a placebo consumed before&#xD;
      the evening meal on health outcomes in night shift workers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are assigned in random order to two conditions, for 12 days each. The&#xD;
      interventions are 1) a 30g whey protein preload consumed 1-1.5 hr prior to their main evening&#xD;
      meal every day for 12 days. No other advice will be given. 2) an identical mixed-nutrient&#xD;
      drink matched for caloric content, taste and palatability consumed 1-1.5 hr prior to their&#xD;
      main evening meal every day for 12 days(placebo). Conditions are separated by a 2-week&#xD;
      washout period, during which participants will be encouraged to maintain their habitual diet&#xD;
      and physical activity levels. Metabolic testing will be performed at baseline, and at the end&#xD;
      of both conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemic response</measure>
    <time_frame>12 days (3 hours meal test)</time_frame>
    <description>Change in glucose (AUC) following a standard breakfast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour glucose profiles</measure>
    <time_frame>12 days</time_frame>
    <description>Change in 24-hour glucose profiles assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>12 days</time_frame>
    <description>Change in 24-hour glucose variability (as SD, standard deviation) assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>12 days</time_frame>
    <description>Change in 24-hour glucose variability (as CV, coefficients of variation) assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability</measure>
    <time_frame>12 days</time_frame>
    <description>Change in 24-hour glucose variability (as MAGE, mean amplitude of gylcaemic excursions) assessed by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1</measure>
    <time_frame>12 days (3 hours meal test)</time_frame>
    <description>Change in GLP-1 (AUC) following a standard breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP</measure>
    <time_frame>12 days (3 hours meal test)</time_frame>
    <description>Change in GIP (AUC) following a standard breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon</measure>
    <time_frame>12 days (3 hours meal test)</time_frame>
    <description>Change in glucagon (AUC) following a standard breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>12 days</time_frame>
    <description>Change in fasting and postprandial insulin following a standard breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>12 days (3 hours meal test)</time_frame>
    <description>Change in ghrelin (AUC) following a standard breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PYY</measure>
    <time_frame>12 days</time_frame>
    <description>Change in YY (AUC) following a standard breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>12 days</time_frame>
    <description>Change in fasting adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>12 days</time_frame>
    <description>Change in fasting CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipids</measure>
    <time_frame>12 days</time_frame>
    <description>Changes in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 days</time_frame>
    <description>Changes in systolic blood pressure and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting metabolic rate</measure>
    <time_frame>12 days</time_frame>
    <description>Changes in resting metabolic rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory quotient</measure>
    <time_frame>12 days</time_frame>
    <description>Changes in respiratory quotient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Shift-work Disorder</condition>
  <arm_group>
    <arm_group_label>Whey protein preload condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>whey protein</intervention_name>
    <description>Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.</description>
    <arm_group_label>Whey protein preload condition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.</description>
    <arm_group_label>Placebo condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Night shift workers (with a minimum of 6 months in their current shift work schedule)&#xD;
&#xD;
          -  35-65 years&#xD;
&#xD;
          -  BMI 28.0-35.0 kg/m2; waist circumference &gt; 80cm&#xD;
&#xD;
          -  Weight stable in the past 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those working standard day time hours only, or those who work less than three to four&#xD;
             night shifts per fortnight on average&#xD;
&#xD;
          -  Personal history and/or diagnosis of: diabetes, cancer, major psychiatric disorders,&#xD;
             liver disease, gastro-intestinal surgery or disease (including malabsorption), eating&#xD;
             disorders, anaemia, insomnia or cardiovascular disease, and/or any other condition&#xD;
             deemed unstable by the study physician&#xD;
&#xD;
          -  Taking medications known to alter body composition or metabolism, including (but not&#xD;
             limited to): any medication used to lower blood glucose or antidiabetic medications&#xD;
             (metformin, sulfonylureas, Glucagon-like peptide-1 (GLP-1) analogues [i.e. exenatide],&#xD;
             thiazolidinediones or DPP-IV inhibitors [i.e. 'gliptins']), medications affecting&#xD;
             weight, appetite or gut motility (i.e. diuretics, domperidone, cisapride, orlistat,&#xD;
             phentermine, topiramate)&#xD;
&#xD;
          -  Participants who are taking stable doses (i.e. &gt; 12 months) of androgenic medications&#xD;
             (i.e. testosterone) or SSRI's will not be excluded. Personal history/diagnosis&#xD;
             (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia,&#xD;
             major depressive disorder, bipolar disorder, eating disorders), gastrointestinal&#xD;
             disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia)&#xD;
             insomnia, or any other medical condition, deemed unstable by the study physician&#xD;
&#xD;
          -  Pregnant, planning a pregnancy or breastfeeding&#xD;
&#xD;
          -  Those who have lost or gained &gt;5% of body weight in the last 6 months&#xD;
&#xD;
          -  Those who consume four or more standard drinks on a single occasion at a 'daily or&#xD;
             almost daily' occurrence&#xD;
&#xD;
          -  current smokers of cigarettes/marijuana/e-cigarettes/vaporisers&#xD;
&#xD;
          -  unable to comprehend the study protocol (i.e. due to English language or cognitive&#xD;
             difficulties)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy T Hutchison, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Adelaide</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Hutchison, PhD</last_name>
    <phone>8128 4862</phone>
    <email>amy.hutchison@adelaide.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leonie Heilbronn, PhD</last_name>
    <phone>8128 4838</phone>
    <email>leonie.heilbronn@adelaide.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Adelaide</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy T Hutchison, PhD</last_name>
      <phone>+61 8128 4862</phone>
      <email>amy.hutchison@adelaide.edu.au</email>
    </contact>
    <investigator>
      <last_name>Amy T Hutchison, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Adelaide</investigator_affiliation>
    <investigator_full_name>A/Prof Leonie Heilbronn</investigator_full_name>
    <investigator_title>A/Prof</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

